Advancing Breast Cancer Therapeutics: Targeted Gene Delivery Systems Unveiling the Potential of Estrogen Receptor-Targeting Ligands

被引:0
|
作者
Lee, Jung Ro [1 ]
Kim, Young-Min [2 ]
Kim, Eun-Ji [2 ]
Jang, Mi-Kyeong [2 ]
Park, Seong-Cheol [2 ]
机构
[1] Natl Inst Ecol NIE, Seocheon 33657, South Korea
[2] Sunchon Natl Univ, Coll Engn, Dept Chem Engn, Sunchon 57922, Jeonnam, South Korea
基金
新加坡国家研究基金会;
关键词
G-PROTEIN; NANOCARRIERS; NANOPARTICLES; MECHANISM; THERAPY; TUMOR;
D O I
10.34133/bmr.0087
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Although curcumin has been well known as a phytochemical drug that inhibits tumor promotion by modulating multiple molecular targets, its potential was not reported as a targeting ligand in the field of drug delivery system. Here, we aimed to assess the tumor-targeting efficiency of curcumin and its derivatives such as phenylalanine, cinnamic acid, coumaric acid, and ferulic acid. Curcumin exhibited a high affinity for estrogen receptors through a pull-down assay using the membrane proteins of MCF-7, a breast cancer cell line, followed by designation of a polymer-based gene therapy system. As a basic backbone for gene binding, dextran grafted with branched polyethylenimine was synthesized, and curcumin and its derivatives were linked to lysine dendrimers. In vitro and in vivo antitumor effects were evaluated using plasmid DNA expressing anti-bcl-2 short hairpin RNA. All synthesized gene carriers showed excellent DNA binding, protective effects against nuclease, and gene transfection efficiency in MCF-7 and SKBr3 breast cancer cells. Preincubation with curcumin or 17 alpha-estradiol resulted in a marked dose-dependent decrease in gene transfer efficiency and suggested targeting specificity of curcumin. Our study indicates the potential of curcumin and its derivatives as novel targeting ligands for tumor cells and tissues.
引用
收藏
页数:16
相关论文
共 45 条
  • [31] Antisense oligonucleotide therapeutics with receptor-targeted delivery in triple-negative breast cancer cells via microRNA blockade without passenger strand side effects.
    Jin, Yuan-Yuan
    Wickstrom, Eric
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 54 - 55
  • [32] Docking and Molecular Dynamics Simulation Revealed the Potential Inhibitory Activity of Amygdalin in Triple-Negative Breast Cancer Therapeutics Targeting the BRCT Domain of BARD1 Receptor
    Chatterjee, Prarthana
    Karn, Rohit
    Emerson, I. Arnold
    Banerjee, Satarupa
    MOLECULAR BIOTECHNOLOGY, 2024, 66 (04) : 718 - 736
  • [33] Docking and Molecular Dynamics Simulation Revealed the Potential Inhibitory Activity of Amygdalin in Triple-Negative Breast Cancer Therapeutics Targeting the BRCT Domain of BARD1 Receptor
    Prarthana Chatterjee
    Rohit Karn
    I. Arnold Emerson
    Satarupa Banerjee
    Molecular Biotechnology, 2024, 66 : 718 - 736
  • [34] The anticancer potential of chemical constituents of Moringa oleifera targeting CDK-2 inhibition in estrogen receptor positive breast cancer using in-silico and in vitro approches
    Rida Sultan
    Abrar Ahmed
    Li Wei
    Hamid Saeed
    Muhammad Islam
    Muhammad Ishaq
    BMC Complementary Medicine and Therapies, 23
  • [35] The anticancer potential of chemical constituents of Moringa oleifera targeting CDK-2 inhibition in estrogen receptor positive breast cancer using in-silico and in vitro approches
    Sultan, Rida
    Ahmed, Abrar
    Wei, Li
    Saeed, Hamid
    Islam, Muhammad
    Ishaq, Muhammad
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2023, 23 (01)
  • [36] Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR plus /ER plus breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study
    Palmieri, C.
    Linden, H.
    Birrell, S.
    Lim, E.
    Schwartzberg, L. S.
    Rugo, H. S.
    Cobb, P.
    Jain, K.
    Vogel, C.
    O'Shaughnessy, J.
    Johnston, S. R. D.
    Getzenberg, R. H.
    Barnette, K. G.
    Steiner, M.
    Brufsky, A. M.
    Overmoyer, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S66 - S66
  • [37] Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer
    Wege, Anja Kathrin
    Vladimirova, Valentina
    Solbach, Christine
    Rom-Jurek, Eva-Maria
    Blohmer, Jens-Uwe
    Jank, Paul
    Sinn, Bruno
    Trumpp, Andreas
    Marangoni, Elisabetta
    Engels, Knut
    Weichert, Wilko
    Pfarr, Nicole
    Irlbeck, Christoph
    Polzer, Bernhard
    Ortmann, Olaf
    van Mackelenbergh, Marion
    Denkert, Carsten
    Loibl, Sibylle
    Brockhoff, Gero
    CANCER RESEARCH, 2022, 82 (04)
  • [38] Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer
    Hornberger, J
    Cosler, LE
    Lyman, GH
    AMERICAN JOURNAL OF MANAGED CARE, 2005, 11 (05): : 313 - 324
  • [39] Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors
    Landberg, G
    Östlund, H
    Nielsen, NH
    Roos, G
    Emdin, S
    Burger, AM
    Seth, A
    ONCOGENE, 2001, 20 (27) : 3497 - 3505
  • [40] Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors
    Göran Landberg
    Hanna Östlund
    Niels Hilmer Nielsen
    Göran Roos
    Stefan Emdin
    Angelika M Burger
    Arun Seth
    Oncogene, 2001, 20 : 3497 - 3505